newsfilter
← Latest News
GlobeNewswire·

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland – June 28, 2021Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3